Nichirei Corporation
https://www.nichirei.co.jp/english
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nichirei Corporation
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Allo CAR-T Is Still On The Shelf As Precision Moves On
Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.
Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Nichirei Biosciences, Inc.
- Nichirei Foods Inc.
- Nichirei U.S.A., LLC
- Nichirei Logistics Group Inc.
- Surapon Nichirei Foods Co., Ltd.
- Frigo Logistics Sp. z o.o.
- Nichirei Fresh Inc.
- Imperial Hotel Kitchen Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice